Nextcure Inc. (NXTC) NASDAQ
$3.63 -0.15 (-3.97%)
Market Cap: $100.72M
As of 05/18/22 04:00 PM EDT. Market closed.
Nextcure Inc. (NXTC) NASDAQ
$3.63 -0.15 (-3.97%)
Market Cap: $100.72M
As of 05/18/22 04:00 PM EDT. Market closed.
NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Through its proprietary FIND-IO™ platform, NextCure studies various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop ... read more
NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Through its proprietary FIND-IO™ platform, NextCure studies various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. Its initial focus is to bring hope and new treatments to patients who do not respond to current cancer therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies. read less
Open in:
Open in:
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Heller Kevin N. | Chief Medical Officer | Jul 14, 2020 | Option Exercise | $1.77 | 27,229 | 48,195 | 49,011 | Jul 16, 2020, 04:51 PM |
| Liu Linda | SVP, Research | Nov 27, 2019 | Option Exercise | $0.75 | 55,234 | 41,656 | 55,234 | Feb 21, 2020, 04:11 PM |
| Sofinnova Venture Partners IX, L.P. | 10% Owner | Nov 15, 2019 | Buy | $36.75 | 150,000 | 5,512,500 | 2,671,856 | Nov 19, 2019, 09:47 PM |
| Sofinnova Venture Partners IX, L.P. | 10% Owner | May 13, 2019 | Buy | $15.00 | 400,000 | 6,000,000 | 2,521,856 | May 15, 2019, 05:59 PM |
| SHANNON TIMOTHY M | Director | May 13, 2019 | Buy | $15.00 | 50,000 | 750,000 | 2,254,442 | May 13, 2019, 07:33 PM |
| Khuong Chau Quang | Director | May 13, 2019 | Buy | $15.00 | 350,000 | 5,250,000 | 2,711,013 | May 13, 2019, 07:32 PM |
| Xu Stella | Director | May 13, 2019 | Buy | $15.00 | 125,000 | 1,875,000 | 1,103,570 | May 13, 2019, 07:32 PM |
| CANAAN X L.P. | 10% Owner | May 13, 2019 | Buy | $15.00 | 50,000 | 750,000 | 2,254,442 | May 13, 2019, 07:32 PM |
| ORBIMED ADVISORS LLC | Director | May 13, 2019 | Buy | $15.00 | 350,000 | 5,250,000 | 2,711,013 | May 13, 2019, 07:32 PM |
| Owner | Relationship | Date | Value($) |
| Heller Kevin N. | Chief Medical Officer | 07/14/2020 | 48,195 |
| Liu Linda | SVP, Research | 11/27/2019 | 41,656 |
| Sofinnova Venture Partners IX, L.P. | 10% Owner | 11/15/2019 | 5,512,500 |
| Sofinnova Venture Partners IX, L.P. | 10% Owner | 05/13/2019 | 6,000,000 |
| SHANNON TIMOTHY M | Director | 05/13/2019 | 750,000 |
| Khuong Chau Quang | Director | 05/13/2019 | 5,250,000 |
| Xu Stella | Director | 05/13/2019 | 1,875,000 |
| CANAAN X L.P. | 10% Owner | 05/13/2019 | 750,000 |
| ORBIMED ADVISORS LLC | Director | 05/13/2019 | 5,250,000 |
Period of Report: 12/31/2021
10-K/10-Q Filings: View